Stage 4 signet ring cell carcinoma (SRCC) carries one of the most sobering prognoses in oncology. Median overall survival after diagnosis of gastric SRCC across all stages is roughly 10.5 months, and patients with distant metastatic disease fare considerably worse, with figures varying by the organ where the cancer originates. The picture is complicated by the fact that SRCC behaves differently depending on whether it starts in the stomach, colon, appendix, or elsewhere, and by the reality that standard treatments often work less well against this particular cancer subtype than they do against other forms of adenocarcinoma.
How Signet Ring Cell Carcinoma Differs From Other Cancers
Signet ring cell carcinoma gets its name from the way it looks under a microscope: mucin pushes each cell’s nucleus to the side, creating a shape that resembles a signet ring. That unusual cellular architecture is more than cosmetic. These cancer cells tend to infiltrate tissues individually or in small clusters rather than forming the bulky masses typical of other carcinomas. They spread through the submucosa and deeper muscle layers of an organ, often without disrupting the surface lining. This diffuse infiltration pattern is a major reason the cancer is hard to catch early and hard to treat once it has spread.
Because the cells burrow beneath the surface, standard endoscopic biopsies sometimes miss them entirely. Studies report false-negative rates on superficial biopsy of around 30 to 40 percent, particularly in the stomach, where the disease can thicken the organ wall dramatically while leaving the inner lining looking deceptively normal.1PubMed Central. Signet-Ring Cell Carcinoma Masquerading as Crohn’s Disease: A Diagnostic Challenge in Multifocal Colonic Strictures with Ascites When the stomach is involved, the diffuse wall thickening can produce a condition called linitis plastica, which may require deeper biopsy techniques to confirm malignancy.2PubMed Central. Diagnostic Value of EUS-Guided Fine-Needle Aspiration Biopsy for Gastric Linitis Plastica with Negative Endoscopic Biopsy
Survival Numbers by Primary Site
Stage 4 SRCC survival depends heavily on where the cancer started. The stomach is the most common primary site for signet ring cell histology, and it carries one of the worst prognoses. A retrospective analysis of gastroesophageal SRCC found a median overall survival of 10.5 months across all stages, with a mean of about 2.1 years.3PubMed Central. Gastroesophageal signet ring cell carcinoma morbidity and mortality: A retrospective review For patients diagnosed specifically at stage 4, one series from a single institution reported a one-year survival rate of about 69 percent, meaning roughly a third of patients did not survive even one year after diagnosis.4Annals of Oncology. Results of SRCC cases presenting to AUBMC between 1997 and 2016
In the colon and rectum, SRCC is rarer but similarly aggressive. A large population-based study found that five-year relative survival was about 31 percent for colon SRCC and 20 percent for rectal SRCC across all stages, compared with roughly 57 to 59 percent for ordinary colorectal adenocarcinoma. The survival disadvantage held at every stage, including stage 4.5Journal of Clinical Oncology. Colorectal signet-ring cell carcinoma: Responsive to adjuvant chemotherapy but still a poor prognosis That translates to a profoundly worse outlook once the cancer has spread beyond the bowel.
Appendiceal SRCC is even less common but has its own distinct trajectory. A SEER database analysis of over 500 patients found an overall median survival of 26 months, but for those with distant metastases at diagnosis, median survival dropped to 19 months.6PubMed Central. Clinicopathologic Features and Survival Outcomes of Signet Ring Cell Carcinoma of the Appendix: An Analysis of the Surveillance, Epidemiology, and End Results Database When diffuse peritoneal spread was present, five-year survival was estimated at just 6.7 to 14 percent.7Journal of Surgical Case Reports. A rare case of signet ring cell carcinoma of the appendix Most patients with appendiceal SRCC already have metastatic disease by the time they are diagnosed, with one study finding that 69 percent presented with metastases and 81 percent had high-grade tumors.8PubMed. Effectiveness of treatment modalities for signet ring cell adenocarcinoma of the appendix
Peritoneal Spread and Why It Dominates the Picture
One of the defining features of SRCC at any primary site is its strong tendency to seed the peritoneum, the membrane lining the abdominal cavity. This matters because peritoneal metastases are notoriously difficult to treat and carry a heavy symptom burden, including pain, bowel obstruction, and the accumulation of fluid in the abdomen known as ascites. A Swedish population-based study of colorectal cancer with peritoneal metastases found that patients with signet ring cell features had a five-year overall survival of about 18 percent, compared with 32 percent for non-signet ring cases.9European Journal of Surgical Oncology. Prognosis and clinical characteristics of signet ring cell colorectal peritoneal metastases – a Swedish population-based study Those patients were also younger, more likely to have synchronous peritoneal disease at diagnosis, and more likely to have involved lymph nodes.
The biology behind this peritoneal tropism is not entirely understood, but SRCC cells shed individually rather than in clumps, which may make it easier for them to detach from the primary tumor and implant across peritoneal surfaces. Once seeded, they provoke a fibrotic reaction that stiffens tissues and narrows the bowel, producing symptoms that mimic inflammatory conditions and can delay correct diagnosis.
Cytoreductive Surgery and HIPEC
For cancers that have spread to the peritoneum, surgeons sometimes attempt cytoreductive surgery (removing all visible tumor) combined with heated intraperitoneal chemotherapy, a procedure known as CRS/HIPEC. In many other types of peritoneal disease, this approach can meaningfully extend survival. For SRCC, the results are discouraging. One multi-institutional study found a three-year survival rate after CRS/HIPEC of just 5.7 percent for patients with signet ring cell features, compared with 66.1 percent for patients without signet ring cells. On further analysis, a high peritoneal cancer burden and gastric origin were the strongest predictors of a poor outcome even among the SRCC group.10PubMed. Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival
A separate analysis focused specifically on colorectal SRCC with peritoneal spread reported a median survival of about 14 months after CRS/HIPEC, compared with 35 months for colorectal peritoneal disease of other histologies. Recurrence rates were also higher, affecting nearly 69 percent of the SRCC patients. The authors went so far as to suggest that signet ring cell histology, in the presence of other relative contraindications, should make surgeons think twice before proceeding with this aggressive operation.11PubMed. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology
That said, in appendiceal SRCC the picture is slightly more nuanced. Complete cytoreduction offered the best five-year survival at about 25 percent, though adding systemic chemotherapy did not significantly improve that figure. HIPEC added to surgery showed a clinically meaningful but not statistically significant survival gain in one study (20 percent versus 5 percent at five years).8PubMed. Effectiveness of treatment modalities for signet ring cell adenocarcinoma of the appendix The takeaway is that surgical debulking may still have a role for carefully selected appendiceal and colorectal cases, but for gastric-origin peritoneal SRCC, the benefit of CRS/HIPEC remains very limited.
Chemotherapy Resistance
A persistent frustration in treating stage 4 SRCC is that it often responds poorly to standard chemotherapy. The molecular reasons are becoming clearer. A gene fusion called CLDN18-ARHGAP26/6, which occurs frequently in gastric SRCC, has been linked to worse survival and resistance to the oxaliplatin-and-fluoropyrimidine regimens that form the backbone of gastric cancer treatment. Cells carrying this fusion essentially become harder to kill with conventional drugs.12PubMed Central. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer
Even when chemotherapy does produce a response, the gains tend to be more modest and less durable than what is seen in other gastric or colorectal cancer subtypes. Part of the difficulty is diagnostic: because the cancer infiltrates diffusely and often does not form measurable masses on imaging, it can be hard to assess whether treatment is working using standard criteria. Researchers have begun exploring blood-based and fluid-based biomarkers that might track treatment response more accurately, but these are still in early clinical use.
Emerging Therapies
The molecular profile of SRCC does open some newer doors. One of the most notable developments involves a protein called Claudin 18.2, which sits on the surface of many gastric SRCC cells. Studies have found that over 95 percent of advanced gastric SRCC samples stain positive for Claudin 18.2, with roughly two-thirds showing moderate to strong expression.13PubMed Central. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma That high expression rate makes SRCC a natural candidate for therapies targeting this protein.
Zolbetuximab is a monoclonal antibody directed against Claudin 18.2. In two global phase III trials, combining zolbetuximab with chemotherapy improved survival in patients whose tumors were Claudin 18.2-positive and HER2-negative, a profile that describes the vast majority of gastric SRCC.14PubMed Central. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer The relationship between Claudin 18.2 expression and survival is still being untangled. One study suggested that high expression in diffuse-type gastric cancer (which includes SRCC) trended toward worse survival, while in the intestinal type it trended toward better survival.15Scientific Reports. Prognostic significance of Claudin18.2 expression in patients with gastric cancer That complexity is why ongoing trials continue to refine which patients benefit most.
Immunotherapy with checkpoint inhibitors is also being studied. A trial combining PD-1 blockade with chemotherapy in metastatic esophagogastric SRCC reported an overall response rate of about 52 percent and a disease control rate near 87 percent, with a median progression-free survival of roughly 6.6 months. Patients whose tumors had certain blood-based biomarker profiles achieved much longer progression-free survival, reaching nearly 14 months.16Experimental Hematology & Oncology. Exosomal PD-L1 and lactate versus tissue PD-L1 as biomarkers for clinical outcomes of PD-1 Blockade plus chemotherapy in metastatic esophagogastric signet ring cell carcinoma These numbers are encouraging, though it remains unclear whether the response will translate into the kind of long-term survival improvements patients urgently need. The search for reliable biomarkers to identify which SRCC patients will respond to immunotherapy is one of the most active areas of research in the field.
Krukenberg Tumors and Ovarian Metastases
Women with stage 4 gastric or colorectal SRCC face an additional concern: metastasis to the ovaries, known as a Krukenberg tumor. These metastases are disproportionately common with signet ring cell histology and carry their own prognostic weight. A study of Krukenberg tumors found a median overall survival of 16 months across all primary sites, but when the primary origin was the stomach, median survival dropped to just 11 months. Colorectal-origin Krukenberg tumors did somewhat better at around 21.5 months.17PubMed Central. Clinical characteristics and prognostic analysis of Krukenberg tumor
Surgical removal of ovarian metastases appeared to improve survival in multiple analyses, and the presence of ascites and peritoneal invasion beyond the pelvis were independent predictors of a worse outcome. In gastric-origin Krukenberg tumors specifically, signet ring cell histology was itself an independent predictor of shorter survival even after accounting for other factors, with a hazard ratio of roughly 1.9.18Journal of Cancer. Management Of Synchronous Krukenberg Tumors From Gastric Cancer: a Single-center Experience For women diagnosed with an ovarian mass and a history of gastrointestinal SRCC, rapid evaluation for Krukenberg tumor is essential because the treatment approach differs substantially from primary ovarian cancer.
When and Why Treatment Is Not Received
One often overlooked factor in stage 4 SRCC outcomes is how frequently patients never receive active treatment at all. When SRCC causes significant ascites, patients may be too debilitated for chemotherapy, or clinicians may judge that treatment is unlikely to help given the aggressive biology. A study of gastric cancer patients presenting with ascites found that signet ring cell histology was the only factor independently associated with not receiving treatment, with patients roughly eight times less likely to get chemotherapy compared with those who had other histological types.19Academic Surgical Congress. 86.15 Signet ring cells are associated with treatment non-receipt in gastric cancer patients with ascites
This creates a self-reinforcing problem. SRCC tends to produce more peritoneal disease and more ascites than other subtypes, which in turn makes patients sicker at presentation, which reduces the chance they will be offered or able to tolerate chemotherapy. Survival statistics for stage 4 SRCC partly reflect this treatment gap, meaning they include a substantial number of patients who received best supportive care only.
The Case for Early Palliative Care
Given the aggressive trajectory and limited treatment responses in stage 4 SRCC, palliative care deserves attention early rather than as a last resort. Evidence in advanced gastric cancer broadly shows that proactive palliative care relieves symptoms more effectively and can improve quality of life, and there is growing recognition that controlling symptoms early may actually improve a patient’s functional status enough to make them eligible for further anti-cancer treatment.20PubMed Central. Palliative care for advanced gastric cancer
In practical terms, this means managing pain, nausea, nutritional decline, and ascites from the outset rather than waiting until chemotherapy options are exhausted. For stage 4 SRCC specifically, where malnutrition and bowel obstruction are common complications of peritoneal spread, nutritional support and interventional procedures for fluid drainage can make a meaningful difference in how patients feel day to day, even when the underlying disease continues to progress. Research on early response prediction during palliative chemotherapy suggests that identifying non-responders sooner could spare patients the side effects of ineffective treatment and allow them to focus on quality of life.21PubMed Central. Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer
Why Diagnostic Delays Are So Common
The survival figures for stage 4 SRCC are partly a story about late detection. The diffuse growth pattern that defines this cancer makes it uniquely easy to miss. In the stomach, SRCC can spread through the wall without producing a visible mass, so endoscopy may show only subtle mucosal changes or thickened folds. In the colon, it can cause strictures that look identical to Crohn’s disease on imaging and even on initial biopsy.1PubMed Central. Signet-Ring Cell Carcinoma Masquerading as Crohn’s Disease: A Diagnostic Challenge in Multifocal Colonic Strictures with Ascites Because tumor cells burrow into the submucosa while the surface mucosa stays intact, the standard superficial biopsies taken during endoscopy can come back negative even when cancer is present. Deeper biopsy techniques, including endoscopic ultrasound-guided aspiration, improve the diagnostic yield but are not always performed on the first pass.2PubMed Central. Diagnostic Value of EUS-Guided Fine-Needle Aspiration Biopsy for Gastric Linitis Plastica with Negative Endoscopic Biopsy
This diagnostic elusiveness means that some patients experience months of non-specific symptoms like vague abdominal pain, bloating, or changes in bowel habits before SRCC is identified. By the time the diagnosis is confirmed, the cancer has often already spread to the peritoneum, lymph nodes, or distant organs. The high percentage of patients presenting with stage 4 disease across all SRCC primary sites is not simply bad luck; it reflects a cancer that is genuinely hard to catch at an earlier, more treatable stage.
What Families and Patients Should Know About Quoted Statistics
Survival statistics for stage 4 SRCC are population averages drawn from cancer registries and institutional series. They describe what happened to large groups of patients over specific time periods, and they include patients across a wide range of ages, fitness levels, and treatment intensities. An individual patient’s trajectory can differ substantially. Younger patients with good functional status who can tolerate aggressive multimodal treatment sometimes exceed the median by a wide margin. Conversely, patients with heavy peritoneal tumor burden, ascites, or poor nutritional status at diagnosis tend to have shorter survival than the median would suggest.
The statistics are also evolving. Many of the large registry-based studies that inform current survival estimates were conducted before newer agents like zolbetuximab and checkpoint inhibitors entered clinical use. Whether these newer therapies will meaningfully shift the survival curves for stage 4 SRCC remains an open question, but the number of clinical trials testing novel combinations in this population has increased sharply in recent years, driven in part by the discovery that SRCC’s molecular profile offers more targetable vulnerabilities than was once assumed.